Hemocue WBC Diff – A new solution for classifying and identifying Covid-19 patients
HomeNews and eventsHemocue WBC Diff – A new solution for classifying and identifying Covid-19 patients
Sunday, 05/25/2025
Sunday, 05/25/2025
Currently, the COVID-19 pandemic situation worldwide continues to evolve very complicatedly, greatly affecting the welfare and society of all countries.
In the context of the complex developments of the pandemic globally, the work of monitoring, detecting, and preventing Covid-19 in Vietnam is always a concern and priority of the government. The classification, isolation, of infected, suspected, and those in contact with infected or suspected individuals is crucial for containing the outbreak and limiting the spread of the disease in the community. Individuals with respiratory symptoms (cough, fever, runny nose, sore throat, chest tightness, difficulty breathing, body aches), and those with epidemiological factors (returning from abroad, contact with infected or at-risk individuals...) are guided, screened, and examined separately. However, cases of Covid-19 patients without symptoms are very difficult to detect and are at risk of being overlooked. Therefore, screening tests play an important role in classifying patients. Some studies have indicated that monitoring the neutrophil-to-lymphocyte ratio can be useful in early screening of COVID-19 patients. Patients with a body temperature < 37.3 degrees, without breathing difficulties, are advised to undergo additional WBC tests. If the lymphocyte count is ≥1100 / μL, the patient can self-isolate at home. If the lymphocyte count is < 1100 / μL, further steps must be taken to determine suspected Covid infection. It can be explained that elevated C-reactive protein (CRP) is an important factor in COVID-19 patients and impaired immunity, characterized by lymphopenia, is a feature that needs attention.
The WBC Diff test from HemoCue/Sweden is a quantitative white blood cell test in the patient's whole blood sample. With advantages such as point-of-care testing, can be performed at multiple locations, simple, convenient, results returned in less than a minute with high accuracy, Hemocue WBC Diff is a noteworthy choice for enhancing the ability to monitor and classify patients during the Covid pandemic, thereby reducing the rate of missed infected patients and increasing the effectiveness of disease prevention.
The product has been used in Sweden with guidelines for classifying and identifying suspected COVID-19 patients with the following procedure:
Reference sources: https://www.hemocue.com/en/health-areas/infections/covid-19-and-wbc-diff https://www.nejm.org/doi/pdf/10.1056/NEJMoa2002032?articleTools=true https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa248/5803306 https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30071-0/fulltext